ArticleSkeletal radiology2026
What is the utility of whole-body PET/MRI in the staging of myxoid liposarcoma?
Article in Skeletal radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMyxoid liposarcoma is a soft tissue sarcoma with a unique predilection for metastasis to atypical sites compared to other soft tissue sarcoma histologic subtypes. Does a whole-body (PET/MRI or PET/CT) staging approach, compared to current National Comprehensive Cancer Network (NCCN) guidelines, improve our ability to identify metastatic disease in myxoid liposarcoma? MATERIALS AND
methodsA retrospective analysis identified 31 patients diagnosed with myxoid liposarcoma between 2015 and 2022. Ten patients were staged with standard guidelines and 21 with a whole-body PET modality. Patients who did not complete any staging or had their definitive care performed outside our institution were excluded.
resultsIn the whole-body group, three (14.3%) patients were found to have metastatic disease on initial presentation, while none had metastatic disease in the standard group. During post-treatment surveillance, two patients in the standard group (n = 10) had new metastases discovered by CT chest with/without MRI spine. Three patients in the whole-body group developed new metastases, which were discovered by whole-body PET/MRI in one and MRI spine in two patients. The median SUVmax of the primary tumor site was 2.8 (range 2.3, 3.4), and for metastasis detected on follow-up imaging, the median SUVmax was 3.2 and 2.6 for the whole-body and standard groups, respectively.
conclusionsWhole-body PET modalities for staging myxoid liposarcoma appear to detect initial metastatic disease and new disease during surveillance, at least as well as current NCCN guideline-recommended modalities. Given that the avidity of myxoid liposarcoma is low, the added value of PET imaging may be limited.
Indexed as
Identifiers
41372708What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.